NCT06791603 The Impact of Social Media-delivered Chemotherapy Side Effects Education for Breast Cancer Patients Receiving Chemotherapy
| NCT ID | NCT06791603 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Taipei Medical University Shuang Ho Hospital |
| Condition | Chemotherapy Side Effects |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-01-06 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-01-06 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if a standardized pharmacists-provided education module by social media can improve patients' knowledge of chemotherapy-related side effects. The main questions it aims to answer is: • Do patients who received a standardized pharmacists-provided education module by social media improve their knowledge of chemotherapy-related side effects? Researchers will compare standardized chemotherapy education +video (experimental group) versus chemotherapy handouts (control group). Participants will: * Received standardized chemotherapy education + video or chemotherapy handouts at the first and second chemotherapy section. * Fill out a questionnaire for outcomes assessment.
Eligibility Criteria
Inclusion Criteria: * Breast cancer patients aged 18 or older undergoing their first chemotherapy. * Possess a smartphone and are able to watch videos on it. Exclusion Criteria: * Unable to read or complete questionnaires in Chinese. * Cognitive impairments. * Pregnant women.
Contact & Investigator
Pohung Lin, PharmD
PRINCIPAL INVESTIGATOR
Taipei Medical University Shuang Ho Hospital
Frequently Asked Questions
Who can join the NCT06791603 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chemotherapy Side Effects. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06791603 currently recruiting?
Yes, NCT06791603 is actively recruiting participants. Contact the research team at 19365@s.tmu.edu.tw for enrollment information.
Where is the NCT06791603 trial being conducted?
This trial is being conducted at New Taipei City, Taiwan.
Who is sponsoring the NCT06791603 clinical trial?
NCT06791603 is sponsored by Taipei Medical University Shuang Ho Hospital. The principal investigator is Pohung Lin, PharmD at Taipei Medical University Shuang Ho Hospital. The trial plans to enroll 100 participants.